Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30 and 60 mg) on instragastric pH in healthy subjects
Clive H. Wilder‐Smith, Emma Nauclér(AstraZeneca (Sweden)), Tore Lind(Skaraborg Hospital), Kerstin Röhss(AstraZeneca (Sweden)), Catharina Nilsson-Pieschl(AstraZeneca (Sweden)), Christina Lundin
Cited by 8
Related Papers
Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study
|Helicobacter|1996|575
The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
|Gastroenterology|1999|433
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Comparison of Outcomes Twelve Years After Antireflux Surgery or Omeprazole Maintenance Therapy for Reflux Esophagitis
|Clinical Gastroenterology and Hepatology|2009|150
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140